Apriwell has secured $2.4 million in new investment capital from investors, the company announced today. This funding round will support the continued expansion of the consumer health platform, which focuses on redefining chronic care through a combination of proprietary, IP-protected over-the-counter (OTC) products and a personalized health companion app.
The company operates across key health areas including gastrointestinal health, urology, and central nervous system (CNS) conditions. Apriwell's approach integrates innovative therapies with digital support, aiming to provide accessible and effective multi-modal care for chronic conditions.
Since its establishment in 2020, Apriwell has served over 100,000 consumers across Germany and Austria. The platform has also become a partner of choice for leading pharmaceutical companies in its markets, commercializing innovations through a consumer-first, digitally enabled model designed to enhance engagement and improve health outcomes.
The newly raised capital is planned to accelerate Apriwell's strategic growth initiatives. These plans include expanding its existing product portfolio, enhancing the features and reach of its personalized health companion app, and strengthening its operational capabilities to meet increasing consumer demand.
This investment positions Apriwell to further its mission of building the future of healthcare by delivering integrated solutions that combine innovative products with digital support. The company aims to continue its trajectory of growth and impact in the consumer health sector.
